Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The trial to which you refer was a continuation of the trial that Austrianova started years ago but was unable to complete. That Phase 2b is still scheduled to begin but the more pressing business is new business.
The study with TD2 for malignant ascites is a completely new study designed by Dr Von Hoff, started last year with an expanded study to begin in a couple of weeks. We received ODDfrom the FDA after the first study was completed.
The study to be done in Vienna using an insulin producing Melligen cell line encapsulated in Cell-in-a-Box(R) technology is also a new study.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10118051.htm
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html?print=1
Also bill, Ken Waggoner just joined the company about 15 months ago. He has accomplished amazing milestones in that short period of time... We are very fortunate to have him.
Two studies this quarter. One has already begun as reported today (diabetes) and the one with Dr Von Hoff will begin in approximately 2 weeks from 1/26 for malignant ascites fluid.
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10118051.htm
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html?print=1
Nice, CUIN2... Thanks... Nice to get the sticky up too...
That is a pretty important from Ken Waggoner, Pete. The Diabetes Consortium has gotten these studies started pretty quickly. Two concurrent studies, diabetes and Cancer. Awesome!
Or course not. He does not invest in Biotechs.
The quote is about being patient, holding... for the big pay out. It is imminent, imo.
Holding for imminent earnings...
“The stock market remains an exceptionally efficient mechanism for the transfer of wealth from the impatient to the patient.”
– Warren Buffett
Expanded study with TD2 and more trials to follow. When I say patient, I mean patient. I can wait.
I am investing to help Cancer patients. That is how the stock market is suppose to work. People invest their funds into a venture they want to support. The company can then use those funds to further the venture. When the venture succeeds, it's a win win.
Ken's father died of pancreatic cancer. I don't believe he would dishonor his memory by doing what you suggest.
I think there are lots of sellers and the company is getting ready for the expanded studies. Among other reasons for the current pps.
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html
:). Have a great weekend all!
It's OK. I can and will wait for the story to unfold. This is just one chapter. Cell in a Box(R) technology will have the final word.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html#sthash.i0fJfXC0.dpuf
“The stock market remains an exceptionally efficient mechanism for the transfer of wealth from the impatient to the patient.”
– Warren Buffet
I do not think short. I think long. Yes, I invested to make money. And when choosing the company in which I wanted to invest, I chose a biotech, PharmaCyte Biotech, Inc. PMCB has exclusive rights to CiaB technology.
Cell in a Box(R) technology has so much potential that Dr Von Hoff is now doing a 13 treatment case study for its use to improve the "quality of life" for Cancer patients.
The successes Cell in a Box(R) has, will be a success for all patient stakeholders...
The reason I am focussed on the technology is because I chose to invest in this company based on the technology and its potential.
I expected this to be a long term investment... so while the company is in its start up mode, just in clinical studies and this being on the OTC, I am not bothered by the current pps. It will change, exponentially, imo.
I really do care about this helping patients. I also care about making money. I just know that my money is coming in the long term and directly related to the success of something in which I strongly believe.
I would only be concerned if trials don't go well. So far, I like what I am hearing...
No apology necessary. And, I politefully disagree.
Long here...
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html
A lot has changed in the past 12 years. I would never close a door on an oppotunity because of a past failure. Do you know how many talents would be lost if everyone gave up after a failure?
I, for one, am glad they are trying to get this to market again. And now we have Drs Gunzburg, Salmons and Lohr on our team.
"Never, Never, Never Give Up" once said a very great man.
IMO, this is especially true when you believe in something.
A lot of folks are invested here because they have lost someone close to Cancer and they want to help get a treatment out there to help.
I still see the many possibilities for Cell in a Box technology.
http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html
The market is made up of lots of different individuals and entities. Each having their own agenda.
It is important to make personal decisions and stick by them.
The market can say what it likes but it will not convince me that Cell in a Box(R) is not the next medical breakthrough. I believe it is...
Full article provided below...
PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.
This expanded study is designed to build upon the successful results of the pilot study that was completed by TD2 late last year. In that study, mice bearing an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups with 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.
The new expanded study will use the same ES-2 ovarian cancer model, but in this study, the mice will be divided into 13 different treatment groups with 10 mice in each group. This study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://www.firstwordmedtech.com/node/973245?tsid=12
J, my sentiments exactly. Right now, we are paying the price for supporting the company's efforts. I personally am willing to pay the price. It is a temporary situation.
The potential payoff for all stakeholders is worth it, imo.
You either stand for something or fall for anything.
Holding...
This is a biotech, long-term hold. Hunker down. We will be here a while. Studies and trials take time. This is no place for those who are impatient or in a rush...
"The first preclinical study by TD2 in the U.S. that deals with the effectiveness of PharmaCyte Biotech's pancreatic cancer treatment on the accumulation of malignant ascites fluid that is often associated with the growth of abdominal cancers, including pancreatic cancer, has been completed and positive results were obtained."
http://globenewswire.com/news-release/2014/12/16/691741/10112491/en/Nuvilex-Provides-Shareholder-Update-on-Cancer-and-Diabetes-Programs.html
I agree young wolf. Just have to wait it out...
Unfortunately it can be...
It's good to be working with Dr Von Hoff who's reputation is impeccable, however. He truly wants to help Cancer patients. Also, Ken's father died of pancreatic cancer. These guys know the pain these patients endure.
I trust them...
The PPS is temporary. I am not selling today or anytime before this technology goes to market. If I needed the money right now, I would be concerned. If you make a decision to hold long, you hold long, not scared...
Nobody's gone. No worries. Long-term hold.
I can wait it out. It will be a few months before we know anything about the upcoming study.
I expect there will be a lot of volatility until we get into human trials and beyond. At least that is how I see it for now, anyway...
GLTU
You may have nothing to lose or gain but I guarantee you, there are a lot of other stakeholders, including myself.
The one that appears to be sticking their neck out the most here is Dr Von Hoff. His involvement was posted on the TD2 website almost a year ago.
Now, he wants to expand this study to 13 treatments? He must be a believer, especially since the first study results were good and he and his team will be using the results of this expanded study to design a Phase I/II human trial...
And, there are patients waiting in the wings at PCRT facilities, hoping as well this treatment works.
Lots of stakeholders who have something to lose or gain...
The clinical study at TD2 with Dr Von Hoff and the Pancreatic Cancer Research is a really big deal. Cell in a Box(R) technology could provide a treatment for cancer patients that would literally improve their "quality of life" by relieving pain associated with ascites and possibly making inoperable pancreatic cancer operable.
This is one of the main reasons I am invested with PharmaCyte. CiaB is a revolutionary product and while everyone bemoans the pps, I stay focussed on the long term goal.
That is my position...
PharmaCyte Biotech's Expanded Follow-up Study on Malignant Ascites Fluid Accumulation in Final Stages of Preparation
SILVER SPRING, Md., Jan. 26, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live cell encapsulation technology, Cell-in-a-Box®, today reported that preparations for an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a- Box® capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid are in their final stages. This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.
This expanded study is designed to build upon the successful results of the pilot study that was completed by TD2 late last year. In that study, mice bearing an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups with 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech's pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech's pancreatic cancer treatment and cisplatin.
The new expanded study will use the same ES-2 ovarian cancer model, but in this study, the mice will be divided into 13 different treatment groups with 10 mice in each group. This study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, said, "We are looking forward to this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady. The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it's very painful and can cause breathing problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://www.firstwordmedtech.com/node/973245?tsid=12
Well, I have no idea who is giving you this advise but I will follow my own instincts.
My instincts tell me to follow this man.
http://www.td2inc.com/leadership/daniel-von-hoff
Holding for the long-term. It's easy. Just follow Dr Von Hoff's lead, relax, and enjoy the ride. Destination, patients, "quality of life" enhancements and shareholder value.
We are in a time of transformation. :)
"This is truly an exciting, important time for PharmaCyte Biotech, and I wish to extend my sincere appreciation to our longstanding shareholders for their continued support during this transformational period of our growth," commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
http://www.otcmarkets.com/news/otc-market-headline?id=16686853
What I was surprised about was that a year ago Dr Von Hoff contacted our CEO and asked to get involved with Cell in a Box technology.
http://www.stockmarketmediagroup.com/wp-content/uploads/2014/06/NVLX-CEO-COO-Interview.mp3
Then he designed a whole new type of treatment using CiaB to improve the "quality of life" by treating pain and ascites and he designed a clinical study around this treatement.
Now, he and the Pancreatic Cancer Research Team are expanding the intitial study to 13 treatments with the intent of designing Phase I/II human trials around those results.
I am not surprised about the pps, nor concerned. In the end, Cell in a Box(R) technology will determine the value of this company. And as Ken Waggoner said,
"Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537#ixzz3Q8lKOwzC
The fact that Dr Von Hoff and the Pancreatic Cancer Research Team want to expand the study to 13 different treatments and then design human trials around the results is all I need to know right now.
We have so many things in the fire but having Dr Von Hoff lead the charge for "quality of life" improvements to due treatment of pain and ascites means that this could be fast tracked and to patients quickly in my opinion if trials go well.
http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537
BTW, notice Nasdaq picked up this PR. They must believe it is important and valid...
Absolutely, bull! Just going to sit back, relax and go along for the ride. Very confident with Dr Von Hoff and team conducting the study and designing the Phase I/II trials...
Not true. Let the reader decide for themselves.
Close day prior to PR - .1325
Close on date of PR - .1365
Close day after PR - .133
----
Down from prior day .0035...
Not nearly a collapse, and neither pump and dump, to answer your question.
No doubt! He is definitely a major shareholder!
They are currently doing clinical studies. Clinical studies are not the same as human trials and therefore do not garner as much attention.
However, I have included journal articles regarding Cell in a Box(R) technology and the third addendum showing Nuvilex's Exclusive Rights to this technology.
Also provided is information regarding this technology written by third parties and not paid for by the company as well as Cell in a Box's previous trial data with Austrianova.
http://jnci.oxfordjournals.org/content/106/12/dju417.full
http://www.sec.gov/Archives/edgar/data/1157075/000115707513000007/a3rdfaddnvlx2013.htm (First Right to offer, #7)
http://austrianova.com/wp-content/uploads/2014/09/DRTOA-1-102-final.compressed.pdf
http://austrianova.com/wp-content/uploads/2014/08/pharmaceutics-06-00447-v2.pdf
http://austrianova.com/wp-content/uploads/2014/06/journal.pone_.01020611.pdf
http://www.bioportfolio.com/news/article/2187932/Pharmacyte-Biotech-Experiencing-Marginal-Success-Still-has-Several-Challenges-in-Coming-Year.html
http://smallcapir.com/wp-content/uploads/2015/01/PHCB-EL-BB-IR-Brief.pdf
http://biotechin.asia/2014/12/29/austrianova-starts-a-facility-in-bangkok-for-its-cell-in-a-box-technology/
http://www.forbes.com/sites/jordanterry/2013/04/05/a-skeptics-take-on-nuvilex-after-speaking-with-management-patience-should-be-rewarded/
http://www.forbes.com/sites/jordanterry/2013/03/25/fear-not-every-penny-stock/?partner=yahootix
This is great information Trenton. Do you have a link for your source?
Thanks
I can show you articles about the technology written by third parties but someone else knowing the company's day to day operations/endeavors, without hearing it from the company directly, is like asking $CELG to write an article about what $LLY is doing.
I don't really understand how that makes any sense. The best source is the source. No third party needed to report on what PharmaCyte is doing...
Bill, it is great having you and other longs on here to provide balanced information to allow those looking to shape their own opinions about PharmaCyte, with great Due Diligence.
Yesterday's news gave me added confidence that when we even hear about end points for trials, we will be amazed at possible treatments that could be available to patients if we are successful and approved.
No doubt you have to stand firm here and remember what you own. It will be a while before we get word of how the follow-up study went. In the meantime, the PPS may continue to take a beating.
However, as our CEO said...
" Hopefully, our pancreatic cancer treatment will slow the accumulation of this malignant ascites fluid and thus reduce the number of withdrawals of the fluid that are needed over a given period of time. To our knowledge, there is no other treatment on the market that can accomplish this - particularly in the case of advanced cancers."
http://money.cnn.com/news/newsfeeds/articles/globenewswire/10116902.htm